PHS=Easy Money/No need for the PILL | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy
PHS=Easy Money/No need for the PILL

An SI Board Since March 2001

Posts	SubjectMarks	Bans	Symbol
2	1	0	PHS

Emcee: Rocket Red	Type: Unmoderated

Introduction Market Data Compact

Pheromene Sciences Corp
8/9/00 - Gains Marketing Approval from Therapeutic Products Programme of
PHEROMONE SCIENCES CORP ("PHS-V") - Gains Marketing Approval from Therapeutic Products Programme of - Health Canada for PSC Fertility Monitor(TM)
Pheromone Sciences Corp. (PHS) announced that Health Canada's Therapeutic Product Programme has issued a marketing approval for Pheromone Sciences' PSC Fertility Monitor. This approval permits PHS to market and distribute the PSC Fertility Monitor system throughout Canada under the indicated use of fertility and ovulation prediction. The PSC Fertility Monitor will provide women with four days advance notice of ovulation, thus enhancing effective decision making on family planning. For those women who may want to utilize the device as a birth control aid, it will supplement forms of contraception, such as condoms, diaphragms etc. The PSC Fertility Monitor system is composed of; the PSC Fertility Monitor, a wristwatch like device which displays the fertility status of the user; a communication device to facilitate the upload of data from the wristwatch to a PC for long term storage, analysis and charting, and; proprietary software designed to transmit and convert the uploaded data into a graphical representation of the patient's fertility status.
The PSC Fertility Monitor offers a new user-friendly option in family planning for couples trying to conceive. The PSC Fertility Monitor is a non-invasive method of predicting ovulation through the measurements of ion changes on the surface of the skin. The PSC Fertility Monitor incorporates an interactive microprocessor combined with a biochemical sensor allowing it to take 12 measurements from the skin surface each day, then compute the data in order to predict the status of the user as being not-fertile, fertile or ovulating. The results can then be viewed any time on the LCD screen of the Fertility Monitor, and/or as a graphical printout. No other commercially available ovulation-monitoring device provides as much advanced warning utilizing such user-friendly technology.

In commenting on the announcement, Pheromone Sciences' President and Chief Executive Officer, Christopher Neuman stated, "We are extremely pleased with the speed at which Health Canada's authorities granted Pheromone the right to market the PSC Fertility Monitor. This crucial milestone in the company's business cycle fully validates our business strategy and technology. With the PSC Fertility Monitor, Canadian women now have an important new tool in their quest for an optimum family planning regimen".

The PSC Fertility Monitor is currently also undergoing "Third Party Validation Trials" at Women's College Hospital in Toronto, under the direction of Dr. Robert Casper. This trial is scheduled for completion in the fall of this year, with the results to support a regulatory filing with the American Food and Drug Administration (FDA) for U.S. marketing approval. Upon FDA approval, PHS plans to commence negotiations for the North American marketing and distribution rights with a strategic commercial partner. The North American market for ovulation and pregnancy test kits in 2000 is forecast to be US$365 million, with a projected annual growth rate of six to seven percent (source: Frost & Sullivan, U.S. Home Diagnostic and Monitoring Product Markets; 1996).

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. This press release contains forward-looking statements. Actual events or results may differ from expectations. Please refer to the risk factors set out in the PHS Annual Information Form. TEL: (604) 872-2012

Nick Borrelly, Director FAX: (604) 872-2098

Corporate Communications

Pheromone Sciences Corp. EMAIL: info@pheromonesciences.com INET : www.pheromonesciences.com

Go to reply# or date (mm/dd/yy):